Cannabis News

InMed Pharmaceuticals announced the filing of a provisional patent application pertaining to the Company’s proprietary biosynthesis program for the manufacture of cannabinoids that are identical to those found in nature.

InMed Pharmaceuticals (CSE:IN; OTCQB:IMLFF) announced the filing of a provisional patent application pertaining to the Company’s proprietary biosynthesis program for the manufacture of cannabinoids that are identical to those found in nature.
As quoted in the press release:

The patent application, once converted into an international Patent Cooperation Treaty (PCT) application and pursued in key jurisdictions throughout the world, will provide significant commercial protection for InMed’s E. coli-based expression system to manufacture any of the 90+ cannabinoid compounds that may have a medical impact on important human diseases.
This will be the first in a series of patent applications directed to various aspects of the Company’s biosynthesis program. In particular, these applications focus on the superior nature of E. coli-based expression systems over other approaches; gene optimization for maximizing the production of cannabinoids and related compounds; and other proprietary developments and data.  The company will actively convert this and subsequent provisional patents into national-stage filings in all major commercial jurisdictions, in due course.

Click here to read the full press release.

Source: www.newswire.ca

MARKETS

Markets
TSX19692.92+236.21
TSXV646.04+10.63
DOW32798.40-46.73
S&P 5004118.63-11.66
NASD12368.98-21.71
ASX6945.20+55.50

COMMODITIES

Commodities
Gold1772.00+10.14
Silver20.34+0.14
Copper3.54-0.01
Palladium2210.00+108.00
Platinum912.50+15.50
Oil93.78-0.11
Heating Oil3.43-0.01
Natural Gas8.19-0.09

DOWNLOAD FREE REPORTS

×